Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Oesclim is a transdermal hormone replacement therapy (HRT) patch that delivers estradiol, the primary estrogen produced by the ovaries. It is indicated for the treatment of moderate to severe vasomotor symptoms (such as hot flushes) associated with menopause, as well as for the prevention of postmenopausal osteoporosis in women at significant risk who are unable to use non-estrogenic medications. By supplementing endogenous estrogen levels, Oesclim helps alleviate menopausal symptoms and supports bone density maintenance in estrogen-deficient postmenopausal women.
Fact Table | |
Formula | C18H24O2 |
License | EMA, US FDA |
Bioavailability | Transdermal: ~20% |
Legal status | Prescription only (Rx-only) |
Chemical Name | Estradiol |
Elimination half-life | 13–20 hours (transdermal) |
Dosage (Strength) | 25 µg/day, 37.5 µg/day, 50 µg/day, 75 µg/day, 100 µg/day (transdermal patches) |
Pregnancy | Contraindicated |
Brands | Oesclim, Estraderm, Vivelle-Dot, Climara, Alora |
Protein binding | 98% |
PubChem CID | 5757 |
MedlinePlus | a605032 |
ChEBI | 16469 |
ATC code | G03CA03 |
DrugBank | DB00783 |
KEGG | D00105 |
Routes of administration | Transdermal, Oral, Intramuscular, Vaginal |
Oesclim is applied once weekly or twice weekly, depending on the prescribed regimen, typically using patches of 25 to 100 micrograms of estradiol delivered per 24 hours. The patch should be applied to a clean, dry, and hairless area of the lower abdomen or buttocks, avoiding the breasts. The application site should be rotated with each new patch to minimize skin irritation. Continuous or cyclical regimens may be used depending on whether the woman has an intact uterus and whether progestogen is co-administered. In women with a uterus, a progestogen should be added to reduce the risk of endometrial hyperplasia.
Each Oesclim patch contains synthetic 17ß-estradiol in varying strengths (e.g., 25, 50, 75, or 100 micrograms per 24 hours), delivered via an acrylate-based adhesive matrix. Inactive components include acrylic copolymer, oleyl alcohol, and a polyester release liner.
Oesclim is contraindicated in women with a history or presence of estrogen-dependent malignancies (e.g., breast or endometrial cancer), undiagnosed abnormal genital bleeding, active or past thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism), known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, myocardial infarction), liver dysfunction or disease, and known hypersensitivity to estradiol or any patch components.
Use with caution in women with risk factors for cardiovascular disease, thromboembolic disorders, or hormone-sensitive malignancies. Estrogen therapy may increase the risk of endometrial cancer when used without a progestogen in women with an intact uterus. Long-term use is associated with increased risks of breast cancer, stroke, and venous thromboembolism. Regular clinical evaluations, including breast and pelvic exams, are advised. HRT should be used at the lowest effective dose for the shortest duration consistent with treatment goals. Periodic reassessment of the need for continued therapy is essential.
Common and serious side effects associated with Oesclim include: